Literature DB >> 17150316

Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro.

V Hengst1, C Oussoren, T Kissel, G Storm.   

Abstract

The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150316     DOI: 10.1016/j.ijpharm.2006.11.024

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  26 in total

Review 1.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

2.  Prevention of orthopedic device-associated osteomyelitis using oxacillin-containing biomineral-binding liposomes.

Authors:  Xin-Ming Liu; Yijia Zhang; Fu Chen; Irine Khutsishvili; Edward V Fehringer; Luis A Marky; Kenneth W Bayles; Dong Wang
Journal:  Pharm Res       Date:  2012-06-26       Impact factor: 4.200

Review 3.  Targeting polymer therapeutics to bone.

Authors:  Stewart A Low; Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-01-28       Impact factor: 15.470

Review 4.  Nanoparticulate systems for growth factor delivery.

Authors:  Sufeng Zhang; Hasan Uludağ
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

5.  Calcium-binding nanoparticles for vascular disease.

Authors:  Deborah D Chin; Sampreeti Chowdhuri; Eun Ji Chung
Journal:  Regen Eng Transl Med       Date:  2018-10-23

6.  Osteotropic therapy via targeted layer-by-layer nanoparticles.

Authors:  Stephen W Morton; Nisarg J Shah; Mohiuddin A Quadir; Zhou J Deng; Zhiyong Poon; Paula T Hammond
Journal:  Adv Healthc Mater       Date:  2013-10-09       Impact factor: 9.933

Review 7.  Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants.

Authors:  Juan Pablo Cattalini; Aldo R Boccaccini; Silvia Lucangioli; Viviana Mouriño
Journal:  Tissue Eng Part B Rev       Date:  2012-05-14       Impact factor: 6.389

Review 8.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

9.  Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice.

Authors:  Diego Dos Santos Ferreira; Bruno Luís Jesus de Oliveira Pinto; Vidhya Kumar; Valbert Nascimento Cardoso; Simone Odília Fernandes; Cristina Maria Souza; Geovanni Dantas Cassali; Anna Moore; David E Sosnovik; Christian T Farrar; Elaine Amaral Leite; Ricardo José Alves; Mônica Cristina de Oliveira; Alexander Ramos Guimarães; Peter Caravan
Journal:  Nanomedicine       Date:  2017-03-23       Impact factor: 5.307

10.  Engineering nanocages with polyglutamate domains for coupling to hydroxyapatite biomaterials and allograft bone.

Authors:  Bonnie K Culpepper; David S Morris; Peter E Prevelige; Susan L Bellis
Journal:  Biomaterials       Date:  2013-01-11       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.